HighTide FY26 H1 net loss widens 46.9% to RMB 167.27 million

• Hightide Therapeutics posted a net loss of RMB 167.27 million, widening from RMB 113.86 million a year earlier.
• Other gains swung to a loss of RMB 86.99 million from a gain of RMB 5.22 million, driven by RMB 86.2 million FVTPL losses on Apollo.
• R&D costs fell 65.4% to RMB 36.83 million, mainly on a RMB 62.3 million drop in third-party contracting expenses.
• Administrative expenses more than doubled to RMB 43.5 million, attributed to higher professional service fees; finance costs more than doubled to RMB 3.26 million.
• China’s NMPA accepted HTD1801’s T2DM NDA in March; cash and bank balances totaled RMB 270.28 million at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309474), on August 31, 2026, and is solely responsible for the information contained therein.